Health Care & Life Sciences » Biotechnology | Intercept Pharmaceuticals Inc.

Intercept Pharmaceuticals Inc. | Ownership

Companies that own Intercept Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Management & Research Co.
4,165,289
14.09%
519,842
0.05%
06/30/2018
The Vanguard Group, Inc.
1,851,994
6.26%
415,333
0.01%
06/30/2018
BlackRock Fund Advisors
1,843,200
6.23%
657,774
0.01%
06/30/2018
SSgA Funds Management, Inc.
1,328,409
4.49%
-68,646
0.01%
06/30/2018
Senvest Management LLC
976,127
3.3%
-175,905
6.98%
06/30/2018
JPMorgan Investment Management, Inc.
923,488
3.12%
-268,947
0.03%
06/30/2018
First Trust Advisors LP
840,584
2.84%
22,310
0.17%
06/30/2018
Sarissa Capital Management LP
635,300
2.15%
0
12.57%
06/30/2018
Citadel Advisors LLC
613,221
2.06%
570,891
0.09%
06/30/2018
Bellevue Asset Management AG
570,367
1.93%
-7,252
0.92%
06/30/2018

About Intercept Pharmaceuticals

View Profile
Address
10 Hudson Yards
New York New York 10001
United States
Employees -
Website http://www.interceptpharma.com
Updated 07/08/2019
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.